Medullary Thyroid Cancer Clinical Trials

6 recruiting

Medullary Thyroid Cancer Trials at a Glance

8 actively recruiting trials for medullary thyroid cancer are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Bethesda, Hefei, and Changsha. Lead sponsors running medullary thyroid cancer studies include Chia Tai Tianqing Pharmaceutical Group Co., Ltd., M.D. Anderson Cancer Center, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse medullary thyroid cancer trials by phase

Treatments under study

About Medullary Thyroid Cancer Clinical Trials

Looking for clinical trials for Medullary Thyroid Cancer? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Medullary Thyroid Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Medullary Thyroid Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

Non-Medullary Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)500 enrolled1 locationNCT01109420
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Not Applicable

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Pancreatic Neuroendocrine TumorMedullary Thyroid CancerAdrenal Cortical Carcinoma+1 more
Shanghai Jiao Tong University School of Medicine21 enrolled1 locationNCT06141369
Recruiting

Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

Cultural AdaptationMedullary Thyroid Cancer (MTC)
M.D. Anderson Cancer Center40 enrolled1 locationNCT07142005
Recruiting

Natural History Study of Children and Adults With Medullary Thyroid Cancer

Medullary Thyroid Cancer
National Cancer Institute (NCI)259 enrolled1 locationNCT01660984
Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

Neuroendocrine NeoplasmParagangliomaPheochromocytoma+23 more
Universidad Nacional Autonoma de Mexico750 enrolled3 locationsNCT06523582
Recruiting
Not Applicable

68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

SurgeryFibroblast Activation Protein InhibitorMedullary Thyroid Cancer+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT06277180
Recruiting
Phase 4

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Medullary Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.360 enrolled19 locationsNCT05830500